All articles by GlobalData Healthcare
GlobalData Healthcare
Alvotech’s AVT05 in Phase III rheumatoid arthritis study, as the sole candidate
There are several anti-TNF therapies on the market for the treatment of rheumatoid arthritis, which include AbbVie’s anti-TNF Humira (adalimumab).
GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia
GlobalData’s annual forecast predicts Ojjaara’s global sales to reach $575m in 2031.
Novo Nordisk’s Wegovy to start being supplied by NHS in England
GlobalData forecasts that the drug will be one of the most successful in the obesity market by 2031.
Market cap rebound by top 20 biopharmaceutical companies in Q2 2023
Eli Lilly witnessed the largest growth in market capitalisation of 36.1% over Q2 2023, propelling the company to the top of the list.
Results from Rybrevant trial solidify Janssen’s foothold in EGFR-mutated NSCLC
Currently, NSCLC patients with EGFR exon 19 deletions or L858R substitution face limited therapeutic options after seeing disease progression post-front-line treatment.
Bristol Myers Squibb’s Reblozyl reinforces market share in first-line MDS Space
According to GlobalData’s analyst consensus forecasts, GlobalData anticipates Reblozyl’s projected total annual sales to reach $3.2bn by 2029.
Eli Lilly’s Mounjaro approved on NHS for use in type 2 diabetes
Mounjaro as a therapy for T2D is likely to gain significant uptake in the primary care space, as well as eventually in specialist weight loss management services.
Record number of respiratory syncytial virus (RSV) designations awarded in 2022
RSV, a common infectious disease of the lungs and respiratory tract, can cause further health problems such as bronchiolitis and pneumonia.
Direct oral anticoagulants’ positive effects on cancer-associated VTE
Direct oral anticoagulant (DOAC) use may not be approved in VTE cancer patients, but GlobalData KOLs share that these drugs are becoming commonplace as a treatment.
New 2023 guidelines for the management of cardiomyopathies
Dr Baigini noted that most of the guidelines are new, rather than an update on existing guidelines, with the exception of the section on hypertrophic cardiomyopathy (HCM).